OBIO CAAP Company: ImmunoBiochem Wins at RESI San Francisco Innovation Challenge
ImmunoBiochem, an OBIO CAAP company solving the problem of tumor heterogeneity won 2nd place at the highly competitive RESI San Francisco Innovation Challenge last week, during the JP Morgan Investor Conference.